California Public Employees Retirement System bought a new position in shares of Alector Inc (NASDAQ:ALEC) during the third quarter, Holdings Channel.com reports. The fund bought 10,893 shares of the company’s stock, valued at approximately $157,000.
Several other institutional investors and hedge funds have also recently modified their holdings of ALEC. Virtus ETF Advisers LLC bought a new position in shares of Alector in the 2nd quarter worth $251,000. Wells Fargo & Company MN grew its position in Alector by 89.2% in the 2nd quarter. Wells Fargo & Company MN now owns 13,650 shares of the company’s stock valued at $259,000 after purchasing an additional 6,434 shares during the period. Rhumbline Advisers increased its stake in Alector by 214.7% during the 3rd quarter. Rhumbline Advisers now owns 31,829 shares of the company’s stock valued at $459,000 after purchasing an additional 21,716 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Alector by 150.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 32,156 shares of the company’s stock valued at $611,000 after purchasing an additional 19,302 shares in the last quarter. Finally, Citadel Advisors LLC bought a new stake in Alector during the 2nd quarter valued at $798,000. Institutional investors own 49.75% of the company’s stock.
ALEC stock opened at $19.76 on Friday. Alector Inc has a twelve month low of $13.64 and a twelve month high of $27.00. The company has a quick ratio of 6.56, a current ratio of 6.57 and a debt-to-equity ratio of 0.19. The stock’s 50 day moving average is $16.75 and its 200-day moving average is $17.53. The firm has a market capitalization of $1.36 billion and a PE ratio of -4.28.
ALEC has been the topic of a number of recent research reports. ValuEngine lowered shares of Alector from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Zacks Investment Research upgraded shares of Alector from a “sell” rating to a “hold” rating in a report on Monday, November 11th. BTIG Research initiated coverage on shares of Alector in a research report on Wednesday, November 27th. They set a “buy” rating and a $28.00 target price for the company. Finally, Cowen restated a “buy” rating on shares of Alector in a report on Tuesday, November 12th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $27.00.
In related news, VP Calvin Yu sold 1,315 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $19.39, for a total transaction of $25,497.85. Also, insider Robert Paul sold 4,000 shares of the company’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $20.00, for a total transaction of $80,000.00. Insiders sold a total of 32,815 shares of company stock valued at $562,348 over the last three months. 34.40% of the stock is currently owned by insiders.
Alector, Inc, a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease.
See Also: How to Trade Using Analysts Ratings
Want to see what other hedge funds are holding ALEC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alector Inc (NASDAQ:ALEC).
Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.